Literature DB >> 19618439

Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.

Dong Hwee Kim1, Steven R Zeldenrust, Phillip A Low, Peter J Dyck.   

Abstract

This study assesses the value of standard quantitative autonomic (QAT) and sensation (QST) tests in detecting, characterizing, and quantitating the severity of transthyretin amyloid polyneuropathy (TTR-A-PN). This information is needed for prospective therapeutic trials, epidemiologic surveys, and medical practice. We reviewed 36 patients with TTR-A-PN who were evaluated between 1997 and 2007. They had neurologic, genetic, electrodiagnostic, and autonomic reflex screen evaluations and allowed their medical records and test results to be evaluated for research purposes. Of these, 22 patients had also been tested by quantitative sensation tests (QSTs). The median symptom duration was 4 years (range 1-30 years). Among quantitative nerve tests evaluated, composite scores of nerve conduction (Sigma5 NC nds), a composite score of QSTs (Sigma3 QST nds), and quantitative autonomic tests (QSART, HR(db), and CASS) gave high frequencies of abnormality. The results show that peripheral autonomic and small-fiber sensory dysfunction was prominent and characteristic of most of the patients we studied. However, this involvement was not selective for small-diameter sensory and autonomic nerve fibers; large motor and sensory fibers were also shown to be dysfunctional. Dysfunction of large fibers was approximately as frequent as that of small fibers. This study provides a rationale for the use of QAT, QST, and Sigma5 NC nds as standard, objective, and quantitative measures for assessing the severity of TTR-A-PN in epidemiologic surveys, therapeutic trials, and medical practice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19618439      PMCID: PMC2735590          DOI: 10.1002/mus.21332

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  40 in total

1.  Vitreous involvement in familial amyloidotic neuropathy: a genealogical and genetic study.

Authors:  O Sandgren; U Drugge; G Holmgren; A Sousa
Journal:  Clin Genet       Date:  1991-12       Impact factor: 4.438

Review 2.  A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected.

Authors:  T Coelho; A Sousa; E Lourenço; J Ramalheira
Journal:  J Med Genet       Date:  1994-04       Impact factor: 6.318

3.  Type I familial amyloid polyneuropathy. A pathological study of the peripheral nervous system.

Authors:  G Sobue; N Nakao; K Murakami; T Yasuda; K Sahashi; T Mitsuma; H Sasaki; Y Sakaki; A Takahashi
Journal:  Brain       Date:  1990-08       Impact factor: 13.501

4.  Peripheral nerve pathological findings in familial amyloid polyneuropathy: a correlative study of proximal sciatic nerve and sural nerve lesions.

Authors:  N Hanyu; S Ikeda; A Nakadai; N Yanagisawa; H C Powell
Journal:  Ann Neurol       Date:  1989-04       Impact factor: 10.422

5.  Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure.

Authors:  P A Low
Journal:  Mayo Clin Proc       Date:  1993-08       Impact factor: 7.616

Review 6.  Autonomic nervous system function.

Authors:  P A Low
Journal:  J Clin Neurophysiol       Date:  1993-01       Impact factor: 2.177

7.  Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: a clinicopathologic, histochemical, immunohistochemical, and ultrastructural study.

Authors:  K Takahashi; S Yi; Y Kimura; S Araki
Journal:  Hum Pathol       Date:  1991-06       Impact factor: 3.466

8.  Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy.

Authors:  P P Costa; A S Figueira; F R Bravo
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

9.  Thermoregulatory sweating abnormalities in diabetes mellitus.

Authors:  R D Fealey; P A Low; J E Thomas
Journal:  Mayo Clin Proc       Date:  1989-06       Impact factor: 7.616

10.  Quantitative sudomotor axon reflex test in normal and neuropathic subjects.

Authors:  P A Low; P E Caskey; R R Tuck; R D Fealey; P J Dyck
Journal:  Ann Neurol       Date:  1983-11       Impact factor: 10.422

View more
  17 in total

Review 1.  Amyloid neuropathies.

Authors:  Susan C Shin; Jessica Robinson-Papp
Journal:  Mt Sinai J Med       Date:  2012 Nov-Dec

2.  Primary amyloidosis presenting as upper limb multiple mononeuropathies.

Authors:  Jennifer A Tracy; Peter J Dyck; P James B Dyck
Journal:  Muscle Nerve       Date:  2010-05       Impact factor: 3.217

3.  Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J J Figueroa; P J B Dyck; R S Laughlin; J A Mercado; R Massie; P Sandroni; P J Dyck; P A Low
Journal:  Neurology       Date:  2012-02-22       Impact factor: 9.910

4.  Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.

Authors:  Teresa Coelho; Luis F Maia; Ana Martins da Silva; Marcia Waddington Cruz; Violaine Planté-Bordeneuve; Pierre Lozeron; Ole B Suhr; Josep M Campistol; Isabel Maria Conceição; Hartmut H-J Schmidt; Pedro Trigo; Jeffery W Kelly; Richard Labaudinière; Jason Chan; Jeff Packman; Amy Wilson; Donna R Grogan
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

5.  Cardiac and peripheral vasomotor autonomic functions in late-onset transthyretin Val30Met familial amyloid polyneuropathy.

Authors:  Haruki Koike; Tomohiko Nakamura; Atsushi Hashizume; Ryoji Nishi; Shohei Ikeda; Yuichi Kawagashira; Masahiro Iijima; Masahisa Katsuno; Gen Sobue
Journal:  J Neurol       Date:  2017-10-05       Impact factor: 4.849

6.  Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers.

Authors:  Jean-Pascal Lefaucheur; Sophie Ng Wing Tin; Philippe Kerschen; Thibaud Damy; Violaine Planté-Bordeneuve
Journal:  J Neurol       Date:  2013-01-11       Impact factor: 4.849

7.  ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable.

Authors:  Thomas H Brannagan; Michaela Auer-Grumbach; John L Berk; Chiara Briani; Vera Bril; Teresa Coelho; Thibaud Damy; Angela Dispenzieri; Brian M Drachman; Nowell Fine; Hanna K Gaggin; Morie Gertz; Julian D Gillmore; Esther Gonzalez; Mazen Hanna; David R Hurwitz; Sami L Khella; Mathew S Maurer; Jose Nativi-Nicolau; Kemi Olugemo; Luis F Quintana; Andrew M Rosen; Hartmut H Schmidt; Jacqueline Shehata; Marcia Waddington-Cruz; Carol Whelan; Frederick L Ruberg
Journal:  Orphanet J Rare Dis       Date:  2021-05-06       Impact factor: 4.123

8.  Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort.

Authors:  Nath Pasutharnchat; Chamaiporn Taychargumpoo; Yongkasem Vorasettakarnkij; Jakkrit Amornvit
Journal:  BMC Neurol       Date:  2021-05-22       Impact factor: 2.474

9.  Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial Presentation.

Authors:  Giulietta Riboldi; Roberto Del Bo; Michela Ranieri; Francesca Magri; Monica Sciacco; Maurizio Moggio; Nereo Bresolin; Stefania Corti; Giacomo P Comi
Journal:  Case Rep Neurol       Date:  2011-02-23

10.  Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis.

Authors:  Ernst Hund
Journal:  Appl Clin Genet       Date:  2012-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.